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We developed a sensitive and accurate analytical method forquantifying methyleugenol (ME) in
human serum. Our method uses a simple solid-phase exraction followed by a highly specific
analysis using isotope dilution gas chromatography-high resolution mass spectrometry. Our
method isvery accurate; its limitofdetection is 3.1 pg/gand its averagecoefficient ofvariation is
14% over a 200-pg/g range. We applied this method to measure serum ME concentrations in
adults in the general U.S. population. MEwas detected in 98% ofoursamples, with a mean ME
concentration of24 pg/g (range < 3.1-390 pg/g). Lipid adjustment ofthe data did not alter the
distribution. Bivariate and multivariate analyses using selected demographic variables showed
onlymarginal relationships betweenrace/ethnicity and sex/fasting statuswith serum ME concen-
trations. Although no demographic variable was a good predictor ofME exposure or dose, our
data indicate prevalent exposure of U.S. adults to ME. Detailed pharmacokinetic studies are
requiredto determine therelationship between MEintake andhuman serum ME concentrations.
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Methyleugenol (ME), or 4-allyl-1,2-
dimethoxybenzene (Figure 1A), is a
compound that occurs naturally in clove oil,
nutmeg, allspice, walnuts, and a variety of
other spices and herbs (1). Currently, ME is
approved by the U.S. Food and Drug
Administration for use in foods either as a
component of a natural product additive or
as a food additive itself. ME is commonly
used in its natural and synthetic forms as a
flavoring agent in dessert foods, an attractant
in insecticides, and a fragrance in perfumes
and soaps (2). More than 30,000 kg ME is
used per year by the food, perfume, and pes-
ticide industries in the United States (3).
Some commercial products that may contain
ME include ice cream, cookies, pies, candy,
soft drinks, chewing gum, gingerbread,
eggnog, pates, ketchup, chutney, apple but-
ter, cigarettes, potpourri, perfumes, and
insecticides. As a flavorant and fragrance,
ME is used in commercial products at
concentrations ranging from 5 to 52 ppm
and 0.002 to 0.3%, respectively (2). It has
been estimated that the average human con-
sumes approximately 6 pg ME/day (1).
Because of the structural similarity of
ME to other carcinogenic allylbenzene flavo-
rants such as safrole and estragole (Figure 1B
and C, respectively), attention has been
focused on the carcinogenic potential of
ME. Miller et al. (1) dosed mice with 4.75
pmol (846 pg) ME administered by
intraperitoneal injections from 1 to 22 days
after birth (1). Hepatic tumors were found
in 70 and 96% of the mice sacrificed after
13 months and between 13 and 18 months,
respectively. More recently, data obtained by
the National Toxicology Program at the
National Institute of Environmental Health
Sciences (NIEHS) clearly implicated ME as
a rodent carcinogen (4,5). In a 2-year study
with doses given 5 days/week, liver neo-
plasms and other tumors were observed in
rats administered ME by oral gavage (5).
Although ME toxicity has been studied in
laboratory animals (1,3,4-6), little or no
information is available on human exposure
and possible adverse health outcomes. Both
toxicologic and human exposure data are
needed to make accurate risk evaluations. The
National Center for Environmental Health
(NCEH) at the Centers for Disease Control
and Prevention (CDC) in Atlanta, Georgia,
and the NIEHS are collaborating to acquire
these data. NCEH investigators are character-
izing human exposure to a variety ofenviron-
mental chemicals by measuring internal doses
(the concentration ofthat chemical, its prima~
ry metabolite, or reaction product in a human
specimen) in the general population to deter-
mine the so-called reference range for a chem-
ical in a population (7). Such ranges supply
information about the prevalence ofexposure
to selected chemicals and the background
concentration range found in humans. These
ranges also serve as a basis for trend studies,
which are designed to determine whether
human exposure to a given chemical is
increasing or decreasing over a given time
period. For toxicologic purposes, these refer-
ence ranges can help prioritize chemicals for
testing. For example, chemicals found in a
high proportion ofthe population or in high
concentrations in certain segments of the
population could be given a high priority for
these toxicologic studies (8,9). In the case of
ME, however, the toxicologic studies were
performed first, and they indicated significant
carcinogenic activity (5). Efforts then focused
on human exposure to ME and the compara-
tive pharmacokinetics of ME in humans and
rodents. To our knowledge, these are the first
data reported on the levels of ME or its
metabolites in the blood or urine ofhumans.
The literature detailing the measurement
ofME or its metabolites in biologic matrices
is scant. In support of NIEHS toxicokinetic
studies that identified ME as a multisite
rodent carcinogen, Graves and Runyon (3)
developed a method for measuring ME in
denatured rat plasma using high-performance
liquid chromatography (HPLC) with ultravi-
olet (UV) detection. The range ofquantifica-
tion ofthe method was 50 pg/L to 10 mg/L,
with coefficients of variation (CVs) ranging
from 0.5% at the high calibration end to
12.5% at the low calibration end. Fischer
and Dengler (10) reported a more sensitive
HPLC-LTV method for the analysis ofa sim-
ilar compound, eugenol, in bile, urine, and
serum after a hexane or C18 solid phase
extraction (SPE). This method had limits of
detection (LODs) of 2, 10, and 10 pg/L in
urine, serum, and bile, respectively, and CVs
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of < 4%. Although both of these methods
may have adequate sensitivity for measuring
ME concentrations in biologic media from
dosed animals, they lack both the sensitivity
and selectivity for measuring trace levels of
ME in biologic samples that result from
everyday human exposures.
We developed a sensitive and accurate
method for quantifying ME in human
serum. Our method uses a simple solid-phase
extraction followed by ahighly specific analy-
sis using isotope dilution gas chromatogra-
phy-high resolution mass spectrometry
(GC-HRMS). As a part of a CDC/NIEHS
collaborative effort (including detailed
pharmacokinetic studies), we applied this
method to measure serum concentrations of
ME in thegeneral U.S. population.
Materials and Methods
Materials. We obtained ME and 3',4'-
(methylenedioxy)-acetophenone (MDA)
(Figure 1D), the recovery standard, from
Aldrich Chemical Co. (Milwaukee, WI).
ME and MDA had purities of99 and 98%,
respectively. Allyl-13C3 methyleugenol
(13C3-ME) of 99% isotopic purity was syn-
thesized by Cambridge Isotope Laboratories
(Andover, MA). We purchased formic acid
(98%) and anhydrous sodium sulfate from
EM Industries (Gibbstown, NJ) and
Mallinkrodt Chemical Co. (Paris, KY),
respectively. All solvents were analytical
grade and were purchased from Burdick and
Jackson (Muskegon, MI). We used all ofthe
chemicals and solvents without further
purification. All reagents were made daily
with bioanalytical grade I water, which we
prepared in-house using a 0.2-pm water fil-
tration system (Millipore, Bedford, MA) and
an Organic-Pure ultraviolet light treatment
reservoir (Barnstead, Newton, MA).
Analytical standards. Individual stock
solutions were prepared by dissolving 5-mg
amounts of ME, 13C3-ME, and MDA
(Figure ID) in 100 mL toluene. We created
eres ii r- .Fr:1 -7-_S.:.. :-%. .1 -, ss.
Figure 1. The chemical structures of (A) ME, (B)
safrole, (C) estragole, and (D) methylenedioxyace-
tophenone. *Carbon atoms that were labeled with
13C forthe ME internal standard.
seven standard sets (0.2, 0.4, 2, 4, 10, 40,
and 100 pg/pL) to encompass the entire lin-
ear range ofthe method. The ME concentra-
tion in each standard set was varied, but the
13C3-ME and MDA concentrations were
kept constant at 40 pglpL. The standard sets
were divided into aliquots and stored at -
20°C until used.
Internalstandard We prepared an inter-
nal standard spiking solution by diluting the
stock 13C3-ME solution with acetonitrile to
a concentration of20 pg/lL. The concentra-
tion was set to obtain the most accurate
analysis possible while maintaining a
repeatable analytical signal.
Recovery standard and diluent. We
made a recovery standard/diluent solution
by diluting the MDA stock standard with
toluene to a concentration of40 pg/pL. This
standard, which we added as the final step
during sample preparation, had a dual
purpose. The toluene served as a keeper to
prevent the extract from completely evapo-
rating. The MDA was the standard against
which 13C3-ME recovery in individual
samples was determined.
Quality controlmaterials. We parepared
quality control (QC) materials from residual
sera from multiple donors. We purchased
the sera from the local Red Cross. Sera were
combined and well mixed. Particles > 0.2
pm were filtered from the pooled serum
using a sterile filtration apparatus. We split
the filtered serum into three equal volume
pools. One pool was not enriched, and
therefore reflected the native or endogenous
concentration of ME in the serum. The
other two pools were enriched with different
levels of ME. Thus, we obtained QC pools
with native low (= 100 pg/g) and high
(= 250 pg/g) ME concentrations. After
enrichment, all pools were mixed for 24 hr
under refrigeration. We dispensed serum
from each pool into vials in 4-mL aliquots.
The vials were capped, labeled, and stored at
-20°C until their use. We determined the
mean concentration and the analytic vari-
ance by the repeat measurement of at least
20 samples in different analytical runs for
each QC pool. A QC run was unacceptable
ifeither the QC sample result for the current
run was outside the upper or the lower 99%
control limit, or the QC sample results for
the current and most recent previous run
were both outside the same upper or lower
95% control limit.
Reagent blanks. Because virtually all
serum samples that we tested had detectable
levels of ME, reagent blanks consisted of 4
mL freshly prepared water. The blank con-
tained the same water used in the daily
preparation of reagents. We prepared the
reagent blanks in the same manner as the
unknown samples.
Sample preparation. We prepared
unknown serum samples, QC materials, and
reagent blanks identically. All sera, reagents,
andstandardswere brought to room tempera-
ture. We weighed a 4-g aliquot ofserum into
a test tube. The serum was spiked with 400
pg 13C3-ME as an internal standard, mixed,
and allowed to equilibrate for approximately
5 min. The serum proteins were denatured
with 4 mL 50% formic acid. We passed the
denatured serum through a preconditioned
Empore C18 SPE column (3M, Harbor City,
CA) and then discarded it. The SPE column
was washed with 2 mL purified water and
eluted with 5 mL methylene chloride. The
eluate was passed through a 500-mg silica gel
SPE column topped with approximately 1 g
anhydrous sodium sulfate and then collected.
We rinsed the column with 2 mL methylene
chloride andcollected andcombined the rinse
with the sample. A TurboVap evaporator
(Zymark Corporation, Hopkinton, MA) set
at 37°C and 15 psi head pressure ofnitrogen
concentrated the extract to approximately 300
pL. We transferred the concentrate to a 1-mL
conical vial. We added a 10-pL aliquot ofthe
recovery standard/diluent to the vial and then
allowed the sample to evaporate to approxi-
mately 10 pL at ambient temperature. We
capped the vial and stored it under refrigera-
tion until analysis.
Instrumentalanalysis. We analyzed 2 pL
of the concentrated extract using splitless
injection GC-HRMS. We performed the
analyses using an HP 5890 or HP 6890 gas
chromatograph (GC; Hewlett Packard Co.,
Wilmington, DE) interfaced with a
VG250/70S or a VG70SE mass spectrometer
(MS; Micromass, Manchester, UK) with
Opus operating software (version 3.5,
Micromass) and equipped with a low-energy
(30 eV) electron impact ionization source.
We achieved separation on a 30-m J & W
DB-5MS [(5% phenyl)-methyl polysiloxane,
0.25-pm film thickness, 0.25-mm id] capil-
lary column J&W Scientific, Folsom, CA).
We used helium with a linear velocity of 35
cm/sec as the carrier gas. The injector and
transfer line temperatures were 260°C. The
initial column temperature, 80°C, was held
for 1 min, increased to 122°C at 30C/min,
then increased to 272°C at 30°C/min, and
held for 1 min. We operated the MS in single
ion monitoring (SIM) mode with an initial
accelerating voltage of 7,000 and a 10,000
resolution, as defined at 10% valley. We used
perfluorokerosene (PFK) ions as lockmasses.
We monitored two ions for ME: one for
quantifying and one for confirming the
presence of ME. One ion each was moni-
tored for 13C3-ME and MDA. Table 1
shows the ions monitored in each channel,
the channel times, and the interchannel
delay times. We recorded the appropriate
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analysis specifications in an acquisition pro-
gram initiated immediately after the injection
ofthe sample into the GC. The total analysis
time persample was approximately 20 min.
Dataprocessing andanalysis. Data were
automatically processed using OpusQuan
software (version 6.1; Micromass), which was
supplied with the mass spectrometers. The
detection threshold and baseline were both set
at 0% in OpusQuan; the peakdifferential was
3, and the minimum peak width was 1. In
addition, the background signal was subtract-
ed and all data were smoothed. The retention
times and areas were automatically entered
into an R:BASE database (Microrim,
Redmond, WA) and the ratios ofthequantifi-
cation and confirmation ions were calculated.
Because ofthe specificity ofHRMS, interfer-
ences were rare; however, any interferences
that occurred were easily recognized because
ofa dramatic shift in the ratio ofthe areas of
the quantification and confirmation ions. In
these instances, the data were deemed unac-
ceptableandtheanalysiswas repeated.
Quantification. We constructed calibra-
tion curves with seven ME concentrations
plotted against the response factors. We
calculated the response factors as the area of
the ME quantification ion divided by the
area ofthe 13C3-ME ion. At least five repeat
determinations were performed for each
concentration on the calibration curve.
Calibration standard concentrations
encompassed the entire linear range of the
analysis. The lowest standard concentrations
were at orbelow the LOD to ensure linearity
and accuracy at the low concentration end.
A linear regression analysis ofthe calibration
plot provided a slope and intercept from
which unknown sample concentrations
could be determined. The intercept was not
statisticallydifferent from zero.
Method validation. We calculated the
analytical LOD for the method as 3 so, where
sowas the average signal in the blanks. For the
instrument LOD, we estimated s0 as the y-
intercept of a linear regression analysis of a
plot ofthe absolute standard deviation versus
the concentration (11). To evaluate ME
recovery, we used 20 serum samples whose
endogenous ME concentrations were well
characterized. Before extraction, we spiked
four samples with ME to a final concentra-
tion of 20 pg/g and four to 100 pg/g; four
were not spiked. The samples were extracted
as previously described. Control samples were
extracts of the unspiked serum spiked after
extraction with ME to final concentrations of
20 and 100 pg/g. The extracts ofall samples
were spikedwith the internal standard to cor-
rectforinstrumental variation during analysis.
We determined ME recovery at each concen-
tration by comparing the spiked samples to
the control samples. Additionally, we deter-
mined the recovery of13C3-ME ofeach indi-
vidual sample by referencing the area of the
13C3-ME ion to the areaofthe MDAion.
We determined the method accuracy by
enriching serum samples with a known
amount ofME, preparing and analyzing the
samples, and then comparing the calculated
and the expected ME concentrations. We per-
formed a linear regression analysis on a plot of
the calculated concentration versus the expect-
ed concentration. With this analysis, aslope of
1.0wouldbe indicativeof100% accuracy.
Table 1. Characteristics ofanalysis by GC-HRMS.
Mass Channel Interchannel
Analyte Ion assignment time (msec) delaytime (msec) Ion use
ME 178.0994 [MJT 160 20 Quantification
ME 163.0759 [M-CH3J+ 160 20 Confirmation
PFK 168.9888 - 50 20 Lock mass
ME-13C3 181.1094 [M]+ 160 20 Quantification
MDA 164.0473 [M*] 160 20 Recovery
12,000
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,. 8,000
C 6,000
4,000
2,000
O M
100 140 10
Massto charge ratio Masstochargeratio
Figure 2. Electron impact mass spectra of (A) ME and (8) 13C3-ME with important mass assignments. M
and L refer to the molecular ion ofthe native and labeled ME, respectively. The fragmentation of the two
compounds is nearly identical with only a 3-amu difference in the predominant ions. Only fragments with
masses > 100 amu were monitored. Smaller fragments (< 100 amu) were in a region with a higher back-
ground signal, therefore increasing the potential for interferences.
Reference range determination. Using
this method, we determined the range ofME
in a subset of serum samples collected from
human adults who participated in the Third
National Health and Nutrition Examination
Survey (NHANES III). NHANES III was
conducted between 1988 and 1994 by the
National Center for Health Statistics
(NCHS/CDC). All protocols were reviewed
and approved by a human subjects review
committee and complied with all national
and institutional guidelines for the protection
of human subjects. NHANES III was
designed to accuratelyrepresent the U.S. civil-
ian noninstitutionalized population; however,
the serum specimens used in ourstudywere a
convenience sample ofthe residual NHANES
III specimens and were not necessarily repre-
sentative of the U.S. population. However,
the samples analyzed in our study were from
adults who represented a diverse spectrum of
sex, age, race and ethnicity, urban and rural
residences, and geographic location variables.
We obtained questionnaire data from each
participant. These data encompassed a vari-
ety of topics ranging from dietary intake to
health status. The questionnaire data that
were considered potentially important factors
affecting serum ME concentrationswere used
in the statistical analysis and interpretation of
the serum ME data. All ME data were log-
transformed before analysis using univariate,
bivariate, and multivariate procedures. We
considered data statistically significant when
p < 0.05. All data analyses were performed
using SAS statistical software (SAS Institute,
Cary, NC).
Results and Discussion
The lackofionizable functional groups on the
allylbenzene carbon skeleton of ME (Figure
IA) facilitated its simple and efficient extrac-
tion from the serum matrix using a C18 SPE
sorbent. We added a second SPE column in
the extraction procedure to further dean the
sample. This silica gel cleanup of the serum
extract removed coextracted compounds with
polar functional groups and also removed
residual water. In repeated recovery experi-
ments at three ME concentrations, the total
recovery of ME from serum was essentially
quantitative. In addition, the recoveryof13C3-
ME, which was determinedindependendyfor
eachsample,wasconsistently > 90%.
The addition of an isotopically labeled
standard (13C3-ME) before sample manipu-
lation, a technique known as isotope dilu-
tion (12), afforded us many advantages.
Chemically, 13C -ME behaves almost
identically to ME, Lut they are distinguish-
able based on the 3 atomic-mass-unit (amu)
difference in their masses and respective frag-
ment ions (Figure 2). For this reason, the
ratio between their ions can internally correct
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for recovery of ME in each individual sam-
ple, which eliminates the need for recovery
surrogates, although a surrogate can still be
used for validation purposes. The automatic
recovery correction reduces the error associat-
ed with the measurement and ultimately
increases the method sensitivity.
During GC-HRMS analysis ofME with
low energy (30 eV) electron impact ioniza-
tion (El), the predominant ions were [M]+,
[M-CH3]+, and [M-OCH3]+ at mass to
charge ratio (m/z) of 178, 163, and 147,
respectively (Figure 2). As expected, higher
energy (70 eV) El produced more fragmen-
tation, especially lower molecular weight
fragment ions, and chemical ionization using
methane as a reagent gas produced only one
ion at mlz 179, [M + H]+. Because the con-
trolled fragmentation at 30 eV resulted in
higher molecular weight ions in a region
with fewer background ions and ions of
higher intensity, we opted to use low energy
El for the analysis. Under these conditions,
the 13C3-ME formed similar ions as ME in
the same relative abundances except that the
mlz of the ions were 3 amu greater (Figure
2). This confirmed that the fragment losses
were not from the allyl group that was
labeled with 13C atoms. We used the MDA
as a recovery standard because ofits structural
similarity to ME and because its predominant
ions were within a few atomic mass units of
ME ions, as is necessary for high-resolution
SIM analysis. MDAeluted from the gas chro-
matography column approximately 2 min
after ME, thus allowing their ions to be mon-
itored in separatewindows oftime (Figure 3).
The instrument LOD was 282 fg on-col-
umn. With the method recovery, this
translates to approximately 350 fg/g serum
(parts per quadrillion); however, ME was
endogenous in the air and water. Using asol-
vent trap on the vacuum system or pulling
excess air through the SPE columns caused a
low-level ME contamination ofapproximate-
ly 5 pg/g (parts per trillion). By removing the
solvent trap andcarefully monitoring thevol-
ume of air pulled through the columns, we
were able to reduce the contamination to
approximately 1 pg/g or lower. Additionally,
we used in-house purified water in reagent
preparation because bottled water and dis-
tilled water contained higher endogenous
ME levels. As a result, the method LOD was
3.1 pg/g. Thereafter, an occasional contami-
nant appeared, but it was readily apparent in
thequalitycontrol samples.
Figure 4 shows a calibration curve. The
ME analysis was linear over 3 orders ofmag-
nitude; r2 = 0.997. We obtained similar
calibration curves on multiple high-
resolution instruments.
The method's accuracy was essentially
100%. A linear regression analysis of a plot
of the calculated concentrations of spiked
samples versus the expected concentrations
of the same samples (Figure 5) yielded a
slope of0.997, which is indicative ofa high
degree ofaccuracy. We used a similar plot to
compare data from multiple instruments;
the plot yielded a slope of 0.996, signifying
good agreement among instruments.
A typical quality control Shewart plot is
shown in Figure 6. This plot includes
samples analyzed on multiple instruments
and reflects both intra- and interday varia-
tion. The overall CV and the intra- and
interday variations at three concentrations
over the linear range of the method are
shown in Table 2. As expected, the variation
among days was a greater contributor to the
overall CV than the variation within days.
Additionally, the variation was greater as the
concentration approached the method
LOD; although this is a normal occurrence,
the low-level contamination ofME probably
resulted in increased variation at the low
concentration end.
Overall, the data from the QC materials
proved that ME was stable in serum over the
testing period of approximately 2 months.
We did not conduct stability studies over
longer periods of time. However, our data
indicate that NHANES III samples had ME
concentrations comparable to freshly collect-
ed serum from volunteers. These data sug-
gest that ME is stable in frozen serum stored
for up to 5 years.
Our method is more sensitive and more
selective than the only published method
(3); for example, the LOD ofour method is
> 4 orders of magnitude lower than the
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Figure 3. Ion chromatograms of a 0.2-pg/pL standard show the clean separation of the components. The
(A) quantification, (B) confirmation, and (C) internal standard ions of ME. (D) The MDA recovery standard.
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Figure 4. (A) A calibration curve for ME over a 100-pg range. r2 = 0.997. (8) The low concentration end
demonstrates the linearity even nearthe LOD.
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LOD of the HPLC-UV method. Some of
the sensitivity differences between the two
methods can be attributed to the decreased
sample size for the HPLC-UV method.
The Graves and Runyon (3) method uses
only 200 pL plasma, whereas our method
requires 4 g serum (the approximate
amount of serum from one 10-mL blood
draw). Because our method uses HRMS, it
provides a greater selectivity than the
HPLC-UV method; this selectivity proba-
bly accounts for a large portion of the
increase in method sensitivity. In addition,
our sample preparation provides a much
cleaner extract, which can help minimize
interfering serum components. The CVs of
our method at very low serum concentra-
tions (Table 2) are comparable to the CVs
(12-12.5%) of the HPLC-UV method at
50 mg/L plasma (3). At higher plasma con-
centrations, the HPLC-UV method reports
CVs ranging from 1-5%.
The specificity ofHRMS at 10,000 reso-
lution was required to eliminate interfering
components in the human serum extracts
that in turn provided the low detection limits
Expected concentration (pg/g)
Figure 5. Plots of the calculated ME concentra-
tion from spiked serum sample extracts against
the expected ME concentration. The slope ofthe
resultant linear regression analysis was 0.997,
indicating a high degree of accuracy in the
calculation.
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Figure 6. A Shewart plot of quality control materi-
als demonstrates the precision of our method.
The mean is 255 pg/g, with a total CV of 8.9%. The
outlier on this plot indicates an occurrence of
contamination (i.e., blank samples that had high
ME concentrations).
ofthe method. Analysis at lower resolutions
resulted in recurring interferences, as evi-
denced bysignificant changes in the ratios of
the quantification and confirmation ions.
These specificity requirements precluded the
use ofsingle quadrupole or other low-resolu-
tion mass spectrometers. However, we did
evaluate the effectiveness of GC-MS (SIM
mode) and GC-tandem mass spectrometry
(MS/MS) for ME analysis using a quadru-
pole ion trap with external ionization (GCQ;
Finnigan MAT, San Jose, CA). The instru-
ment LODs in the SIM and MS/MS modes
were 50 and 3.4 pg on-column, respectively.
Although the SIM mode did not provide the
sensitivity required for ME analysis in serum,
the MS/MS LOD was adequate. The
calculated concentrations of QC materials
analyzed using both the GC-HRMS and
GC-MS/MS analyses are shown in Table 3.
The GC-HRMS clearly provided more
accurate and precise data.
Table 4 shows a summary of the serum
ME concentrations (whole-weight basis) in
206 adult participants ofNHANES III. The
distribution of the data (Figure 7) was not
altered when the individual ME concentra-
tions were adjusted for total lipid content in
each serum sample. The frequency of ME
detection was 98%, which verified that our
analytical method had adequate sensitivity to
detect incidental exposure to ME and that
Table 2. Variation in ME analyses.
Concentration
Low Mid High
Parameter (12 pg/g) (130 pg/g) (225 pg/g)
Total CV(%) 21 13 8.9
InterdayCV(%) 22 12.5 9.3
IntradayCV(%) 9.6 7.5 7.2
Replicates (n) 69 60 48
Table 3. Calculated concentrations in spiked qual-
ity control pools using GC-HRMS and GC-MS/MS.
Pool
Low concentration
Mid concentration
High concentration
Concentration
GC-HRMS GC-MS/MS
(pg/g) (pg/g)
12 (21%) Notquantifiable
130(13%) 122 (63%)
225(9%) 360(19%)
CVs are shown in parentheses.
Table 4. ME distribution in serum of adult partici-
pants in NHANES Ill.
Statistic Value
Adults (n) 206
Detection frequency 98%
Mean 24pg/g
Median 16 pg/g
Minimum ND
Maximum 390 pg/g
5th percentile 5 pg/g
95th percentile 78 pg/g
ND, not detected or < 3.1 pg/g.
the population as a whole is exposed to ME
to some extent. Only four individuals had
ME concentrations below the LOD (< 3.1
pg/g). Five individuals had serum ME levels
. 100 pg/g, which is approximately 2 times
the average peak serum ME concentrations
observed in fasting adults fed a meal con-
taining approximately 60 1ig ME (4).
Bivariate and multivariate analyses ofthe
data using the demographic information
proved only marginally significant at best.
Males who fasted for > 9 hr before providing
a serum sample had, on average, lower ME
levels than those who fasted for < 9 hr
(Table 5). Females displayed the opposite
trend. The interaction between sex and fast-
ing status was marginally significant (p =
0.0449). Even though the interaction was
marginally significant, further testingdid not
indicate any significant differences among
the groups. Non-Hispanic blacks had lower
average ME levels than non-Hispanic whites,
MexicanAmericans, and other ethnic groups
(Table 5); however, the differenceswere only
nominallysignificant (p = 0.0847).
Differences among the other demograph-
ic variables were nonsignificant; however,
some general trends were interesting and
worth noting. Smokers had slightly higher
ME levels than nonsmokers. In general, peo-
ple living with nonsmokers had lower ME
levels than those living with one smoker;
both of these groups had lower ME levels
than peoplelivingwith two or moresmokers.
Other data demonstrating nonsignificant
trends are shown in Table 5.
Although the demographic information
did not provide data that would help predict
which factors were strong determinants of
ME exposure in the general U.S. population,
the data provided interesting information.
Most ofthe trends that we observed were not
surprising. For instance, because ME is a fla-
voring agent in many commercial products, it
seems plausible that smoke resulting from
commercial cigarettes could contribute, in
part, to serum ME levels. Although the differ-
ences were not significant, the fact that these
trends existedwarrants further investigation.
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Figure 7. Distribution of ME in the serum of
NHANES Ill participants.
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Table 5. Geometric mean (GM) concentration and distribution characteristics of serum ME in selected
demographic categories.
ME concentrations (pg/g)
Percentile
Demographic group No.a GM Min 25th 50th 75th Max
Male
All 64 17 3.9 12 16 27 110
Fasting < 9 hr 23 19 4.3 13 17 31 110
Fasting > 9 hr 41 16 3.7 11 15 24 84
Female
All 142 16 2.2 job 17 22 390
Fasting < 9 hr 56 14 2.2 lob 16 20b 54
Fasting > 9 hr 86 18 2.2 lob 18 24 390
Race/ethnicity
Non-Hispanic white 53 19 4.9 12 18 29 84
Non-Hispanic black 96 14 2.2 8.8 15 22 390
Mexican American 41 19 5.4 14 18 23 110
Other 16 16 5.2 13 17 19 78
Age group
18-26 years 48 16 2.2 13 17 22 390
27-34years 54 16 4.1 lob 15 22 95
35-42 years 43 16 2.2 11 17 22 110
43+years 61 17 2.2 11 18 24 160
Smoking exposure status
Nonsmoker and no 107 5.6 2.2 9.5 16 22 390
smokers in home
Smoker or living 69 17 2.2 11 15 23 160
with 1 smoker
Smoker or living with 28 19 4.9 12 16 29 110
.2 smokers
Drinks bottled water
Yes 29 19 5.8 14 20b 24 95
No 175 16 2.2 lob 15 22 390
Diet
<1 cake/colaperday 114 16 2.2 11 17 23 160
> 1 cake/cola perday 92 17 2.2 11 16 22 390
Abbreviations: max, maximum; min, minimum.
'Total number in demographic group. 1Zero is a significant digit.
The ME exposure data in adults of the
general U.S. population provide invaluable
information. Considering that in male and
female rats, oral ME doses of75-150 mg/kg
resulted in peak average plasma ME concen-
trations ranging from 1.5 to 8.2 mg/L
(1.5-8.2 ppm) and that these same dose lev-
els clearly induced malignant lesions in rats
and mice on a chronic daily basis (5), the
human serum ME concentrations observed
in our study population suggest that more
extensive risk evaluation is needed. Assuming
that humans respond similarly to rodents,
these human ME data coupled with hazard
identification data (i.e., Does a chemical rep-
resent a potential health hazard?), compara-
tive human and rodent pharmacokinetic
data, and rodent dose-response data should
provide adequate information to characterize
human risk of cancer as well as noncancer
health effects resulting from ME exposure.
It is important to emphasize that these
human data are from adults only. Considering
the potential sources of ME exposure and
children's small size, it is likely that children
would have higher concentrations of ME.
Exposure and risk assessment in children is
an extremely important area in which to
focus future ME studies.
Conclusions
We developed a highly specific, accurate, and
sensitive method for the measurement ofME
in human serum using isotope dilution
GC-HRMS. We applied this method to
analyze ME concentrations in the serum of
adult participants in NHANESIII. The high
frequency ofME detection in this population
verified that our method possessed adequate
sensitivity for ME analysis in the general
population. The data also indicated that
exposure to ME in the U.S. population is
prevalent. Because no potential determinants
of exposure were significantly correlated
with ME concentrations, we surmise that the
total ME exposure is from a variety of
sources. Substantial serum concentrations of
ME in fasting adults, coupled with ubiqui-
tous low levels ofME in air and water, sug-
gest that ME exposure results from foods
where ME is not intentionally added as well
as from nonfood sources. These human data
coupled with hazard identification and
rodent dose-response data provide the
necessary information for proper human risk
assessment for ME.
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